What are the effects of Phenethylamine (compound)?

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism. It is also worth noting that thes

Phenethylamine (compound)

Stimulants

Phenethylamine (2-phenylethylamine, PEA) is a naturally occurring monoamine alkaloid and the parent compound of the phenethylamine chemical class — one of the most pharmacologically important molecular scaffolds in psychopharmacology. In its base form, PEA is a trace amine found endogenously in the mammalian brain, where it functions as a neuromodulator influencing monoaminergic tone. As a chemical class, "phenethylamines" encompasses an enormous structural family including endogenous neurotransmitters (dopamine, norepinephrine, epinephrine), entactogens (MDMA, MDA), classical psychedelics (mescaline, the 2C family, the DOx family, the NBOMe and NBOH series), stimulants (amphetamine, methamphetamine), and appetite suppressants (phentermine).

The core scaffold consists of a phenyl ring (benzene with a phenyl group) connected to an ethylamine chain (NH2-CH2-CH2-). The extraordinary pharmacological diversity of the phenethylamine class arises from systematic substitutions on this scaffold: ring substitutions at the 2, 3, 4, and 5 positions; alpha-methyl or alpha-ethyl substitutions on the aliphatic chain; and N-alkyl substitutions. Different patterns of substitution shift pharmacological activity toward dopaminergic, serotonergic, or noradrenergic receptor systems — and in the case of psychedelic phenethylamines, toward potent 5-HT2A agonism.

The pharmacological mapping of this chemical space was systematized by Alexander Shulgin, whose 1991 book PiHKAL (Phenethylamines I Have Known And Loved) catalogued 179 phenethylamine derivatives with detailed synthesis procedures and subjective accounts — work that established much of the modern understanding of structure-activity relationships in the psychedelic phenethylamine field and that, controversially, made synthesis procedures publicly available, contributing to the emergence of a designer drug market.

Pharmacology

The Core Scaffold

The phenethylamine backbone — a benzene ring connected to an ethylamine chain (C6H5-CH2-CH2-NH2) — serves as the structural foundation for a vast range of pharmacologically active compounds. The scaffold itself produces limited psychoactivity in its unmodified form due to rapid monoamine oxidase (MAO) metabolism; PEA's plasma half-life in humans is measured in minutes. The psychoactive compounds derived from this scaffold typically involve structural modifications that confer MAO resistance, increased lipophilicity, and/or receptor selectivity.

Major Subclasses and Their Mechanisms

Catecholamines (dopamine, norepinephrine, epinephrine) The endogenous catecholamines are hydroxylated phenethylamines serving as neurotransmitters and hormones. They act at adrenergic (norepinephrine, epinephrine) and dopaminergic (dopamine) receptors throughout the nervous and cardiovascular systems. These are not psychoactive when exogenous but are the neurochemical targets of amphetamines.

Amphetamine and methamphetamine Alpha-methyl substitution on the ethylamine chain confers MAO resistance, dramatically increasing duration of action. Amphetamine and methamphetamine act by reversing monoamine transporters (DAT, NET, SERT), causing active efflux of dopamine, norepinephrine, and to a lesser extent serotonin. The dopaminergic component drives stimulation and euphoria; the noradrenergic component drives cardiovascular effects. Methamphetamine's additional N-methyl group increases CNS penetration.

MDMA and entactogens (3,4-substituted phenethylamines) The 3,4-methylenedioxy substitution (forming the ring system of MDMA, MDA) dramatically shifts the pharmacological profile toward potent serotonin release. MDMA and its analogs act as mixed dopamine/serotonin/norepinephrine releasers with a serotonin-dominant profile, producing the characteristic empathogenic, entactogenic effects distinct from pure stimulants.

Mescaline and the 2,5-dimethoxy series 2,5-Dimethoxy substitution on the phenyl ring, often combined with a 4-position substituent, produces psychedelic phenethylamines. Mescaline (3,4,5-trimethoxyphenethylamine) is the archetype. The 2C series (2,5-dimethoxy-4-substituted phenethylamines, developed by Alexander Shulgin) systematically explores the pharmacological effects of different 4-position substituents. Activity is mediated primarily by 5-HT2A agonism.

The DOx series (2,5-dimethoxy-4-substituted alpha-methylphenethylamines) Adding an alpha-methyl group to the 2C scaffold produces the DOx series (DOI, DOB, DOC, etc.). The alpha-methyl group confers MAO resistance and dramatically extends duration of action to 12–24+ hours. DOx compounds are full 5-HT2A agonists with stimulant properties and unusually long duration. They are highly potent at microgram doses and carry significant toxicity risk.

The NBOMe and NBOH series N-(2-methoxybenzyl) or N-(2-hydroxybenzyl) substitution on the terminal nitrogen of 2C compounds produces the NBOMe and NBOH series respectively. These modifications dramatically increase 5-HT2A binding affinity, shifting active doses to the 250–1,000 μg range. NBOMe compounds are among the most potent 5-HT2A agonists known and are associated with confirmed fatalities due to narrow therapeutic windows and vasoconstriction toxicity.

Trace Amine Role

Endogenous phenethylamine (PEA) functions as a trace amine in the brain, modulating monoaminergic tone via trace amine-associated receptor 1 (TAAR1), which acts as an intracellular receptor regulating dopamine and other monoamine neurotransmission. PEA is synthesized from phenylalanine via aromatic amino acid decarboxylase and is present in small amounts in the mammalian brain. Its role in mood regulation and psychiatric conditions including depression and ADHD has been studied but remains incompletely characterized.

MAO Metabolism

The primary pharmacokinetic limitation of unmodified phenethylamine is rapid oxidative deamination by monoamine oxidase type B (MAO-B), which metabolizes PEA to phenylacetaldehyde and then phenylacetic acid. The plasma half-life of exogenous PEA is approximately 5–10 minutes, explaining its limited intrinsic psychoactivity. Structural modifications that confer MAO resistance — alpha-methylation, ring substitution — are the primary structural determinants of duration and potency for pharmacologically active derivatives.

History

Discovery of the Core Scaffold

Phenethylamine itself was isolated and characterized in the early 20th century. Its role as a trace amine neuromodulator was established in the 1970s–1980s, with identification of its endogenous synthesis from phenylalanine and its metabolism by MAO-B. The trace amine receptor TAAR1 through which much of its neuromodulatory function is mediated was characterized in 2001.

Alexander Shulgin and PiHKAL

The most consequential figure in phenethylamine pharmacology is Alexander Shulgin (1925–2014), a Berkeley-trained chemist who worked initially at Dow Chemical (where he developed the first biodegradable pesticide, zectran, making him commercially valuable enough to later receive DEA Schedule I research licenses). Shulgin developed a remarkably productive research collaboration with the DEA in which he synthesized and self-experimented with hundreds of psychoactive compounds. His 1991 book PiHKAL: A Chemical Love Story (co-authored with his wife Ann Shulgin) systematically documented 179 phenethylamine derivatives, including their synthesis procedures and detailed subjective accounts — an unprecedented mapping of chemical-experiential space.

PiHKAL is simultaneously the primary scientific reference for phenethylamine structure-activity relationships, a harm reduction tool (Shulgin's dosage and duration data are widely cited), and a synthesis compendium that contributed to the emergence of the designer drug market by making procedures publicly available. Shulgin's DEA Schedule I licenses were ultimately revoked in 1994 following a raid on his laboratory, though he continued publishing research until his death.

The 2C Family

Shulgin's 2C series — 2,5-dimethoxy-4-substituted phenethylamines — developed as a systematic exploration of the pharmacological effects of different 4-position substituents. 2C-B (4-bromo), 2C-I (4-iodo), 2C-C (4-chloro), 2C-E (4-ethyl), and many others were characterized by Shulgin and subsequently entered recreational drug markets. The 2C series became the structural basis for the later and dramatically more potent NBOMe and NBOH series.

The NBOMe Series and the Designer Drug Era

The NBOMe series, developed by Ralf Heim at FU Berlin in 2004, represented a pharmacological extension of Shulgin's 2C work — applying the N-(2-methoxybenzyl) modification to increase 5-HT2A affinity. The subsequent appearance of NBOMe compounds in drug markets, disguised as LSD, in the early 2010s represented a new category of harm from designer drug development: compounds designed specifically as research tools entering recreational use with inadequately characterized safety profiles and catastrophic consequences.

Legal and Cultural Legacy

The scheduling of MDMA (1985), the DEA's action against Shulgin (1994), the emergency scheduling of NBOMe compounds (2013), and ongoing efforts to control novel psychoactive substances represent the arc of regulatory response to the phenethylamine class. The widespread availability of Shulgin's synthesis procedures and the global designer drug market represent the ongoing challenge of harm reduction in a context where structural analogs can be indefinitely generated faster than regulatory responses can be implemented.

Harm Reduction

Test Your Substance

Reagent testing is essential and varies by substance subclass:

Marquis reagent: Turns purple-black for MDMA; yellow-orange for PMA (critical distinction)
Mecke reagent: Complements Marquis for entactogens
Ehrlich reagent: Turns purple for indoles (LSD, psilocybin); no reaction for phenethylamines — useful for excluding indoles in blotter testing
For any blotter sold as LSD, an absent Ehrlich reaction indicates a phenethylamine compound may be present

Class-Wide Safety Principles

Do not combine with MAOIs The MAOI contraindication is essentially universal for psychoactive phenethylamines. Combining any serotonergic phenethylamine with a MAOI risks serotonin toxicity.

Understand the specific compound you are using The phenethylamine class spans compounds with vastly different safety profiles. The "I'm just taking a phenethylamine" framing obscures critically different risk profiles. PMA, 25I-NBOMe, and MDMA are all phenethylamine derivatives; their risks are not comparable.

Cardiovascular conditions are a class-wide risk factor Elevated heart rate and blood pressure are consistent effects across psychoactive phenethylamines. Underlying cardiac conditions represent elevated risk for all members of the class.

Monitor temperature in warm environments Serotonergic and stimulant phenethylamines elevate body temperature. Warm environments and physical exertion compound this. Take regular cool-down breaks.

The Importance of PiHKAL in Harm Reduction Context

Alexander Shulgin's PiHKAL catalogued the structure-activity relationships of phenethylamine derivatives in unprecedented detail. While this work has been used as a synthesis roadmap for designer drug production, it also provides the pharmacological and subjective basis for understanding how different structural modifications shift psychoactive and toxicological properties. For harm reduction purposes, understanding why different phenethylamines have different risk profiles requires understanding the structural determinants Shulgin catalogued.

Toxicity & Safety

Overview

Phenethylamine (the base compound) has low acute toxicity and limited psychoactivity due to its rapid metabolism by MAO-B. Its derivatives, however, span a wide range of toxicity profiles — from relatively safe recreational compounds (psilocybin analogs at appropriate doses) to highly dangerous substances (NBOMe compounds, PMA) that have caused numerous fatalities.

Class-Wide Risk Factors

Cardiovascular stimulation Virtually all psychoactive phenethylamine derivatives stimulate the cardiovascular system to some degree through catecholaminergic mechanisms. Those with underlying cardiac conditions should approach the entire class with extreme caution.

Hyperthermic potential Multiple phenethylamine derivatives — particularly those with significant serotonergic activity (MDMA, PMA, MDA) or those combining serotonergic and stimulant properties — carry significant hyperthermia risk. Temperature dysregulation is one of the dominant mechanisms of acute fatality across the class.

Serotonin toxicity risk Serotonergic phenethylamines (MDMA, MDA, MDE, PMA, PMMA, high-dose 2C compounds) can produce serotonin toxicity at high doses or in combination with other serotonergic drugs. MAOIs represent an absolute contraindication for essentially all serotonergic phenethylamines.

Neurotoxicity with heavy stimulant use Heavy use of dopaminergic phenethylamines (amphetamine, methamphetamine) is associated with dopaminergic neurotoxicity. Heavy use of entactogens (MDMA, MDA) is associated with serotonergic neurotoxicity. Stimulant-class phenethylamines carry additional risk of psychosis induction with chronic use.

Specific Dangers by Subclass

NBOMe compounds: Fatalities documented; narrow therapeutic window; vasoconstriction
PMA/PMMA: Hundreds of fatalities; extreme hyperthermia; frequently adulterated into MDMA pills
DOx compounds: Long duration creates sustained cardiovascular stress; toxicity at high doses
Methamphetamine: Neurotoxicity, psychosis, cardiovascular events with chronic use
MDMA: Relatively lower acute toxicity risk; significant risk with heavy frequent use

Drug Interactions

MAOIs represent an absolute contraindication for all serotonergic phenethylamines. Specific interactions vary by subclass; see individual substance pages.

Overdose Information

Stimulant overdose from Phenethylamine (compound) is a medical emergency primarily involving cardiovascular and neurological toxicity.

Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.Emergency response:

Call emergency services immediately
Keep the person cool (remove excess clothing, apply cool water)
If seizures occur, protect the head and clear the area of hard objects
If the person loses consciousness, place in recovery position
Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionalsPrevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.

Full	Unknown
Half	Unknown
Zero	Unknown

Phenethylamine (compound)

Dosage

Duration

Subjective Effects

Physical Effects

Physical(8)

Tactile(1)

Cognitive & Perceptual Effects

Visual(3)

Cognitive(11)